ライフサイエンスコーパス: MMC

1 MMC dose of 0.2 vs 0.4-0.5 mg/mL (hazard ratio [HR] 2.51

2 MMC had no effect on acquisition of HSV-2 during 72 mont

3 MMC is irreversible at term.

4 MMC is passively transported and bioreductively activate

5 MMC therapy is a potent inducer of PVOD in humans and ra

6 MMC was important to avoid inaccurate quantification of

7 MMC-induced PVOD in rats represents a unique model to te

8 that had LASIK with the application of 0.02% MMC for 10 s on the stromal bed after excimer laser trea

9 10 years ago: group 1, intraoperative 0.02% MMC for 5 minutes; group 2, LCAU.

10 as increased from 0.55, corresponding to 35% MMC product obtained with the homogeneous catalyst, up t

11 he determination of cathinone derivatives (4-MMC and 4-MEC) in three seized street samples that are i

12 vatives mephedrone (4-methylmethcathinone; 4-MMC) and 4'-methyl-N-ethylcathinone (4-methylethcathinon

13 tored after subcutaneous administration of 4-MMC (1-10 mg/kg ) using an implantable radiotelemetry sy

14 thermoregulatory and locomotor effects of 4-MMC.

15 s catalyst, up to 1.49, corresponding to 60% MMC product.

16 MMC/O ratio up to 2.2, corresponding to >68% MMC product.

17 nd the fellow eyes in both groups (P = 0.926 MMC, P = 0.468 LCAU).

18 ation of DNA-modified electrode in activated MMC led to alterations in DNA and changes in its electro

19 Additionally, MMC is a potent bactericide for a broad range of bacteri

20 omplete success rates compared to adjunctive MMC; however, the risk of persistent hypotony is higher

21 n vitro binding activity was confirmed after MMC conjugation.

22 or in combination with DNA damaging agents (MMC or oxaliplatin) in PDA cell lines that are either DN

23 An MMC conjugate (MMC-TOC) was synthesized on solid-phase a

24 by the spl/nzz mutant failing to develop an MMC.

25 d endothelial cell density (ECD) reported an MMC-related decrease in ECD, no clinical adverse outcome

26 atients (3.1-20.4 years of age) underwent an MMC-augmented primary trabeculectomy during the period f

27 s was reduced 5.8 and 3.8 mm Hg in AgNP- and MMC-treated eyes, respectively.

28 P was reduced 4.1 and 0.2 mm Hg in AgNP- and MMC-treated eyes, respectively.

29 eriods: prior to the availability of ART and MMC (1999-2004), during early availability of ART and MM

30 -2004), during early availability of ART and MMC (2004-2007), and during mature program scale-up (200

31 l Rakai communities, community-level ART and MMC coverage, sociodemographics, sexual behaviors, and H

32 lysis were 100% and 94.4% in bevacizumab and MMC groups, respectively (P = .32, log-rank test).

33 Using conditioned media from control and MMC treated cells, we demonstrate that factors secreted

34 lymphoblasts were hypersensitive to MMC and MMC-induced monoubiquitination of FANCD2 was impaired.

35 tentially achievable by price reductions and MMC interventions targeting F&V intake in the US populat

36 lig4 double mutants toward high salinity and MMC treatments, indicated the involvement of NHEJ-mediat

37 da knockout mutants toward high salinity and MMC treatments, with higher levels of accumulation of do

38 ent of NHEJ-mediated repair of salinity- and MMC-induced DSBs.

39 , and in increased levels of spontaneous and MMC-induced chromatid breaks.

40 As MMC does not inherently possess any anti-cancer activity

41 deficient RecN(K35A) binds and forms foci at MMC-induced DSBs, but is not released from the MMC-induc

42 trol was not significantly different between MMC treatment groups, but older patient age and limbus-b

43 is denied differences in bleb height between MMC vs OLO (140.5 +/- 20.3 mu vs 129.2 +/- 19.3 mu respe

44 However, both MMC + 1% preservative-free lidocaine and 1% preservative

45 his study to identify DNA damages induced by MMC.

46 lls, we demonstrate that factors secreted by MMC-treated corneal epithelial cells attenuate collagen

47 deposition by HCFs whereas those secreted by MMC-treated HCFs do not.

48 mplant) and trabeculectomy with mitomycin C (MMC) (0.4 mg/ml for 4 minutes) in patients with previous

49 raftment potential of HSPC, and Mitomycin C (MMC) -sensitive hematopoiesis), were absent in Rad18(-/-

50 ival injection of a solution of mitomycin C (MMC) and 1% preservative-free lidocaine (as an anestheti

51 ncluding the crosslinking agent mitomycin C (MMC) and the replication inhibitor hydroxyurea, but not

52 Ten eyes received mitomycin C (MMC) and triamcinolone.

53 s and standardized surgical and mitomycin C (MMC) application protocols.

54 e FDA-approved anti-cancer drug mitomycin C (MMC) eradicates persister cells through a growth-indepen

55 o underwent trabeculectomy with mitomycin C (MMC) for uncontrolled elevated intraocular pressure (IOP

56 s were used in 400 cases (93%): mitomycin C (MMC) in 271 (63%), 5-fluorouracil (5-FU) in 129 (30%), a

57 Trabeculectomy with mitomycin C (MMC) is a major treatment option, although both chronic

58 A single application of Mitomycin C (MMC) is used clinically in ophthalmology to reduce scarr

59 ivity to the DNA damaging agent mitomycin C (MMC) that correlates with delayed repair of MMC-induced

60 y on accurate concentrations of mitomycin C (MMC) to prevent scarring with trabeculectomy surgery.

61 in microstent implantation with mitomycin C (MMC) versus trabeculectomy with MMC.

62 ng deep sclerectomy (NPDS) with mitomycin C (MMC) versus XEN(R) gel stent with MMC.

63 Intraoperative mitomycin C (MMC) was associated with reduced failure for IOP of 15 m

64 e (MMS), camptothecin (CPT) and mitomycin C (MMC), agents that hinder the progression of replication

65 creased cellular sensitivity to mitomycin C (MMC), and in increased levels of spontaneous and MMC-ind

66 tivity to crosslinkers, such as mitomycin C (MMC), we find that they are largely resistant to HU, exc

67 ayed higher levels of basal and mitomycin C (MMC)-induced chromosomal abnormalities.

68 , but is deficient in repair of mitomycin C (MMC)-induced DNA damage.

69 ) procedure with application of mitomycin C (MMC).

70 of the DNA cross-linking agent mitomycin C (MMC).

71 ation by the ICL-inducing agent mitomycin C (MMC).

72 and the DNA cross-linking agent mitomycin C (MMC).

73 ot BLM, conferred resistance to mitomycin C (MMC, an interstrand crosslinker) and camptothecin (CPT,

74 implant) or trabeculectomy with mitomycin C (MMC; 0.4 mg/ml for 2 minutes).

75 sess the role of intraoperative mitomycin-C (MMC) application during hyperopic LASIK correction (+ 1.

76 OLO) versus trabeculectomy plus mitomycin-C (MMC) show contradictory results.

77 s of 7 cases of PVOD induced by mitomycin-C (MMC) therapy from the French Pulmonary Hypertension Regi

78 ication and trabeculectomy with mitomycin-C (MMC) vs. Collagen Matrix (CM).

79 We calculated MMC concentration using a calibration curve (range, 0.3-

80 RS-LC-QTOFMS and matrix-matched calibration (MMC) to simultaneously determinate legislated and emergi

81 enarios: (a) a national mass media campaign (MMC) aimed to increase consumption of F&Vs and reduce co

82 Both mass media campaigns (MMCs) and economic incentives may increase F&V consumpti

83 The Multi-Stage Model of Carcinogenesis (MMC), developed in the 1950 s-70s, postulated carcinogen

84 mice with implanted mouse mammary carcinoma (MMC) tumors, after initial tumor growth, tumors regresse

85 Magnetic micro-carriers (MMCs) were functionalized with molecular beacons to enab

86 ed sterility, altered Megaspore Mother Cell (MMC) specification, and delayed programmed cell death in

87 ne is formed from the megaspore mother cell (MMC), a single cell in the premeiotic ovule.

88 l as TGF-beta-treated mouse mesangial cells (MMC).

89 ta-treated mouse glomerular mesangial cells (MMCs).

90 CCR2(+) activated myeloid mononuclear cells (MMCs) and the levels of proinflammatory cytokines in the

91 omatal stem cells (meristemoid mother cells [MMCs]) are fundamental for the generation and patterning

92 ents, we designed a multimodality chelation (MMC) scaffold which combined a radiometal chelating agen

93 ing approach with a multimodality chelation (MMC) scaffold would minimize steric effects of dye conju

94 tion in the number of multiple motile cilia (MMC) covering the cell surface.

95 month efficacy of medical male circumcision (MMC) against herpes simplex virus 2 (HSV-2) incidence am

96 Medical male circumcision (MMC) and antiretroviral therapy (ART) are proven HIV pre

97 asing coverage of medical male circumcision (MMC) and antiretroviral treatment (ART) at CD4 <350/muL.

98 Subjects were divided into 2 cohorts: MMC delivered by sponge application or by intra-Tenon in

99 of dorsally projecting medial motor column (MMC) neurons.

100 Community MMC coverage in males and ART coverage in HIV-positive p

101 Among males, each 10% increase in community MMC coverage was associated with an adjusted IRR of 0.87

102 In Rakai, Uganda, increasing community MMC and female ART coverage was associated with lower co

103 Median community MMC coverage increased from 19% to 39%, and median commu

104 ccur as part of the migrating motor complex (MMC), a contractility pattern of the gastrointestinal tr

105 ation accuracy and variability of compounded MMC are unknown.

106 The resulting compounds, MMC(IR800)-TOC and DA(IR800)-TOC, were labeled with Cu a

107 or metal with minimum metallic conductivity (MMC).

108 ase 1 phosphorylation nevertheless conferred MMC hypersensitivity.

109 An MMC conjugate (MMC-TOC) was synthesized on solid-phase and compared wit

110 g limbo-keratoplasty with conjunctivoplasty, MMC, and AM transplantation is a promising new surgical

111 lasty in conjunction with conjunctivoplasty, MMC, and AM.

112 n phosphate-buffered saline (PBS) (control), MMC (0.2 mg/ml), a mixture of 0.2 mg/ml MMC + 1% preserv

113 in baseline diets, CVD rates, MMC coverage, MMC duration, and declining effects over time.

114 Cu-MMC(IR800)-TOC demonstrated higher potency for cyclic ad

115 th octreotide reduced tumor uptake of (64)Cu-MMC(IR800)-TOC by 66%.

116 dies revealed higher tumor uptake for (64)Cu-MMC(IR800)-TOC than (64)Cu-DA(IR800)-TOC (5.2 +/- 0.2 vs

117 caused a dose-dependent reduction in (64)Cu-MMC(IR800)-TOC uptake whereas (64)Cu-DA(IR800)-TOC was n

118 Excretion of (64)Cu-MMC(IR800)-TOC was primarily through the liver and splee

119 h, the ratio between macro(mono)cyclization (MMC) product and all undesired oligomerization products

120 Three dye-derivatized MMC compounds were synthesized and radiolabeled.

121 (range, 0.3-0.5 mg/mL) generated by dividing MMC peak area by internal standard peak area and plottin

122 cy of OLO as adjuvant compared to low-dosage MMC in trabeculectomy.

123 tm(-/-) single mutant mice survived low-dose MMC similar to wild-type controls, Hus1(neo/neo)Atm(-/-)

124 Acid and electroreductive MMC activations were compared and different adducts were

125 fective HIV prevention strategy is to expand MMC coverage and then scale up ART, but the most cost-ef

126 We find MMC effectively eradicates cells grown in numerous diffe

127 robust Fancd2 mono-ubiquitination following MMC treatment.

128 s incubated in PBS, 0.642 for MMC, 0.612 for MMC + 1% preservative-free lidocaine, and 0.605 for 1% p

129 80 for solutions incubated in PBS, 0.642 for MMC, 0.612 for MMC + 1% preservative-free lidocaine, and

130 ommon compounding and storage techniques for MMC resulted in a lower accuracy and wider range of conc

131 should be tested as a preventive therapy for MMC-induced PVOD in humans.

132 (188 +/- 47 mum, P = 0.285) compared with GS+MMC (109 +/- 26 mum, P = 0.023 to GS) and PS+MMC (48 +/-

133 es were available for analysis; 131 eyes had MMC delivered via sponge and 185 eyes via injection.

134 Here we show in vitro that a 3-hour MMC treatment of primary and telomerase immortalized hum

135 he mean preoperative IOP was 26.7(+/-5.2) in MMC and 27.3(+/-6.0) in OLO eyes.

136 0.0005) from 2.5 (+/-0.3) to 1.2 (+/-0.4) in MMC and from 2.6 (+/-0.2) to 1.4 (+/-0.3) in OLO group,

137 at the </=15 mm Hg target IOP 35% and 45% in MMC and OLO, respectively.

138 nce after incubation of the DNA-biosensor in MMC solution for a known time was used as indication of

139 vercome the immunosuppressive environment in MMC tumors.

140 e of 15.2 (+/-3.2) and 15.8 (+/-2.3) mmHg in MMC and OLO, respectively.

141 FOG2 knockdown by siRNAs in MMC activated Akt and increased the protein content/cell

142 Variability in MMC concentration could cause inconsistency in glaucoma

143 educed central and peripheral vascularity in MMC group (P = 0.027; P = 0.041).

144 study showed similar trends of regulation in MMCs treated with HG or TGF-beta.

145 so by influencing the polarity of individual MMCs.

146 We note that lidocaine did not inhibit MMC cytotoxicity and exhibited a significant cytotoxic e

147 Intraoperative MMC application during hyperopic LASIK achieves better p

148 Intraoperative MMC enhances survival, whereas higher preoperative IOP a

149 graft was more effective than intraoperative MMC in minimizing pterygium recurrence at the 10-year fo

150 y pterygium were treated with intraoperative MMC (n = 63) or LCAU transplants (n = 52).

151 Treatment with intraoperative MMC was not associated with long-term corneal endothelia

152 2 (HSV-2) incidence among men in the Kisumu MMC randomized trial.

153 The measured MMC concentration determined using the high-performance

154 imilar to that of mitochondrial megachannel (MMC) or mitochondrial permeability transition pore (mPTP

155 r identity of the mitochondrial megachannel (MMC)/permeability transition pore (PTP), a key effector

156 ol), MMC (0.2 mg/ml), a mixture of 0.2 mg/ml MMC + 1% preservative-free lidocaine, or 1% preservative

157 ed ectopically, suggesting that the multiple MMC-like cells observed might be attributable to the ect

158 Myelomeningocele (MMC) is a devastating spinal cord birth defect, which re

159 across US adults from 2015 to 2030: national MMCs and national F&V price reductions of 10% and 30%.

160 equitable proportional effects.Both national MMCs and price-reduction policies could reduce US CVD mo

161 Neither MMC nor male ART coverage was associated with lower fema

162 In the MMC and no-MMC groups, 17.6% (3/17) and 55.0% (11/20) of the cases

163 .2 +/- 0.2 and 2.2 +/- 0.3 in the MMC and no-MMC groups, respectively (P = 0.007).

164 mHg and 14.7 +/- 0.9 mmHg for the MMC and no-MMC groups, respectively (P = 0.6).

165 dothelial counts after the administration of MMC during surgery, the clinical significance of this fi

166 In rats, intraperitoneal administration of MMC induced PVOD, as demonstrated by pulmonary hypertens

167 substantiating the clinical applicability of MMC against bacterial infections.

168 The application of MMC by injection was similar to application by sponge in

169 al outcomes of using PRK with application of MMC for enhancement were good.

170 Amifostine prevented the development of MMC-induced PVOD in rats.

171 ere is good evidence of the effectiveness of MMC when used intraoperatively as prophylaxis against ha

172 act of lidocaine on the cytotoxic effects of MMC in this setting.

173 We also demonstrate the efficacy of MMC in an animal model and a wound model, substantiating

174 odeling was used to estimate the efficacy of MMC on HSV-2 risk.

175 A significant fraction of MMC sensitivity is independent of the Fanconi anaemia pa

176 Measurement of MMC using the high-performance liquid chromatography met

177 The MMC group received 0.1 ml of MMC (0.25 mg/ml) injected intraoperatively, at 1 and 4 w

178 We acquired 60 samples of 0.4 mg/mL of MMC from a spectrum of common compounding and storage te

179 The pathological progression of MMC involves failure in neural tube and vertebral arch c

180 understanding of pathological progression of MMC is mandatory for appropriate treatment to be rendere

181 rect monitoring of anti-cancer properties of MMC.

182 (MMC) that correlates with delayed repair of MMC-induced chromosomal DNA damage monitored by pulsed-f

183 surveyed in this report support the role of MMC as an adjunctive treatment in surface ablation proce

184 tro fibroblast cytotoxicity to a solution of MMC (0.2 mg/ml) and 1% preservative-free lidocaine.

185 Both techniques of MMC delivery (subconjunctival injection and direct scler

186 Transfection of MMC with miR-200b/c mimics significantly decreased the e

187 offer an appealing approach for treatment of MMC.

188 here, this would support further scale-up of MMC and ART for HIV prevention in sub-Saharan Africa.

189 Over the past 15 years, the use of MMC during surgery in surface ablation has become widesp

190 onsecutive cases operated without the use of MMC from 2015 to 2017 were compared with consecutive cas

191 rrent topical application of either AgNPs or MMC was performed on 14 pigmented Dutch Belted rabbits.

192 al cancer and were treated with MMC alone or MMC plus 5-fluoruracil.

193 ay result from compounding techniques and/or MMC degradation.

194 als in FANCB-deleted cells exposed to CPT or MMC, respectively.

195 welve of 47 patients (25.5%) in the original MMC group and 2 of 29 patients (6.9%) in the LCAU group

196 In wild-type ovules, MMC differentiation requires SPOROCYTELESS/NOZZLE (SPL/N

197 Amifostine prevents MMC-induced PVOD in rats and should be tested as a preve

198 MMC (109 +/- 26 mum, P = 0.023 to GS) and PS+MMC (48 +/- 30 mum, P = 0.028 to PS).

199 We used pure MMC (Medisca Inc) to generate calibration curves and sul

200 or differences in baseline diets, CVD rates, MMC coverage, MMC duration, and declining effects over t

201 In rats, MMC administration was associated with dose-dependent de

202 us ortholog of CCNO also resulted in reduced MMC and centriole numbers in embryonic epidermal cells.

203 inking an inherited human disease to reduced MMC generation due to a defect in centriole amplificatio

204 s of the opposite sex based on self-reported MMC status and ART use.

205 trict SPL/NZZ expression to specify a single MMC.

206 e same surgical protocol, and a standardized MMC dosage was used.

207 tment strategies including NSAIDs, steroids, MMC and corneal transplants have shown tremendous succes

208 /neo)Atm(-/-) double mutants showed striking MMC hypersensitivity, consistent with a model in which M

209 r a standardized protocol of subconjunctival MMC injections.

210 aoperative and postoperative subconjunctival MMC injections.

211 nlarged cells, consistent with supernumerary MMC-like cells.

212 ial cell adhesion molecule (EpCAM) targeting MMC-immunoconjugate was prepared and dual-labeled with (

213 rrosive nature, the Mg(CB11H12)2/tetraglyme (MMC/G4) electrolyte system permits standardized methods

214 tive-free lidocaine were more cytotoxic than MMC and PBS (P < 0.01 for all).

215 NP-treated eyes showed more lymphocytes than MMC-treated eyes.

216 It was found that MMC did not interact with DNA.

217 ll proliferation and apoptosis revealed that MMC treatment caused severe damage in highly replicating

218 Tukey post hoc comparisons showed that MMC was more cytotoxic than PBS (P < 0.001).

219 The MMC group received 0.1 ml of MMC (0.25 mg/ml) injected i

220 The MMC paradigm was later confirmed, and cancer incidence w

221 The MMC sponge group had significantly more tense, vasculari

222 subunit of F-ATP synthase that activates the MMC/PTP, and were inhibited by Mg(2+) and adenine nucleo

223 A correlation between the MMC/O ratio and the substrate-to-pore-size ratio was suc

224 ngs and gastrointestinal motility during the MMC is largely unknown, however, as is its ability to st

225 0 +/- 0.8 mmHg and 14.7 +/- 0.9 mmHg for the MMC and no-MMC groups, respectively (P = 0.6).

226 C-induced DSBs, but is not released from the MMC-induced DNA lesions, resulting in a defect in homolo

227 However, the MMC has never been tested for its ability to account for

228 1.0 medications (p = 0.63) at 2 years in the MMC and CM groups, respectively.

229 In the MMC and no-MMC groups, 17.6% (3/17) and 55.0% (11/20) of

230 onths was 1.2 +/- 0.2 and 2.2 +/- 0.3 in the MMC and no-MMC groups, respectively (P = 0.007).

231 follow-up period was 138 +/- 2 months in the MMC group and 137 +/- 2 months in the LCAU group.

232 ar blebs without oozing were recorded in the MMC group and 2 (10%) in the OLO group, without intergro

233 an ECD was 2,39 2 +/- 342 cells/mm(2) in the MMC group and 2,390 +/- 388 cells/mm(2) in the LCAU grou

234 ent study, 76 of the 114 patients (47 in the MMC group, 29 in the LCAU group) were contacted, whereas

235 rrent 10-year long-term follow-up (47 in the MMC group, 29 in the LCAU group).

236 mechanisms, need to be incorporated into the MMC to make it capable of generalizing cancer incidence

237 ormance liquid chromatography to measure the MMC concentration of all samples.

238 Neither the MMC nor the individual national economic policies would

239 s is warranted as well as application of the MMC dual labeling approach with other monoclonal antibod

240 which resulted in a further increase of the MMC/O ratio up to 2.2, corresponding to >68% MMC product

241 ngs resolve the long-standing mystery of the MMC/PTP and demonstrate that Ca(2+) can transform the en

242 a(2+) elicits currents matching those of the MMC/PTP.

243 f key somatic evolutionary parameters on the MMC performance, revealing that two additional major mec

244 d receptor pharmacology and suggest that the MMC scaffold is a useful tool for the development of dua

245 aline phosphatase was then conjugated to the MMC surface through biotin-streptavidin interactions.

246 can produce biotin-modified sequences on the MMCs.

247 ted with TNF inhibitors at the time of their MMC-augmented primary trabeculectomy.

248 Therefore, MMC is the first broad-spectrum compound capable of elim

249 rgery, AgNPs are a reasonable alternative to MMC as adjunctive therapy.

250 Compared to MMC, AgNPs result in an improved and sustained reduction

251 s co-deficient of FANCJ and RAP80 exposed to MMC are attributed to single-stranded DNA created by Mre

252 airing DNA damage resulting from exposure to MMC.

253 ate fragmented chromosomes after exposure to MMC.

254 Their lymphoblasts were hypersensitive to MMC and MMC-induced monoubiquitination of FANCD2 was imp

255 Patients were randomized to MMC delivered by preoperative subconjunctival injection

256 beculectomy (10 eyes) and were randomized to MMC or CM.

257 wild-type FANCM improved their resistance to MMC re-establishing FANCD2 monoubiquitination.

258 e role of the 9-1-1 complex in responding to MMC was partially ATR-independent, as a HUS1 mutant that

259 sition by corneal fibroblasts in response to MMC.

260 and long-term success rates quite similar to MMC, with at least equivalent safety.

261 Topical MMC and interferon alpha-2b are an effective treatment m

262 patients treated consecutively with topical MMC (0.4 mg/mL), interferon alpha-2b (1 million units/mL

263 Transient MMC treatment also reduces migration and deposition of t

264 Transient MMC treatment induces HCLE expression of senescence asso

265 iabetic mouse glomeruli and TGF-beta-treated MMC.

266 -mortality reduction strategy is to scale up MMC and ART jointly.

267 When MMC is applied in the appropriate concentration and conf

268 y, we found an increase in cytotoxicity when MMC (0.2 mg/ml) was combined with 1% preservative-free l

269 ensitivity, consistent with a model in which MMC exposure in the context of Hus1 dysfunction results

270 both groups at 24 months: 38.4 +/- 7.6% with MMC and 56.2 +/- 7.9% with CM (mean +/- standard error,

271 tric trabeculectomy technique augmented with MMC is an effective procedure in the management of glauc

272 Comparing communities with MMC coverage more than 40% (mean male community incidenc

273 e risk of persistent hypotony is higher with MMC.

274 o group at 3 months post-op after LASEK with MMC to correct myopia.

275 received an ab externo SIBS microshunt with MMC from July 2015 to November 2017.

276 etween standalone ab interno microstent with MMC and trabeculectomy with MMC.

277 due to persistent hypotony was observed with MMC (p = 0.002).

278 This effect is not observed with MMC treatment, suggesting a non-canonical function for t

279 tion, same-site trabeculectomy revision with MMC should be considered as a viable option to achieve r

280 tomycin C (MMC) versus XEN(R) gel stent with MMC.

281 ses who received trabeculectomy surgery with MMC in an academic medical center.

282 Trabeculectomy with MMC achieved lower IOP with use of fewer glaucoma medica

283 d in patients undergoing trabeculectomy with MMC and in those undergoing Baerveldt implantation durin

284 Tube-shunt surgery and trabeculectomy with MMC are both viable surgical options for managing glauco

285 success rate compared to trabeculectomy with MMC during 5 years of follow-up in the TVT Study.

286 Trabeculectomy with MMC had higher rates of surgical failure and reoperation

287 ts (40 eyes) assigned to trabeculectomy with MMC or Ologen.

288 microstent with MMC and trabeculectomy with MMC.

289 ldt glaucoma implant) or trabeculectomy with MMC.

290 e shunt implantation and trabeculectomy with MMC.

291 mitomycin C (MMC) versus trabeculectomy with MMC.

292 d squamous anal cancer and were treated with MMC alone or MMC plus 5-fluoruracil.

293 ompared with previous topical treatment with MMC (with or without surgery; 29.6 +/- 4.7 months; P = .

294 After treatment with MMC, reduced phosphorylation of the ATR substrate CHK1 o

295 iversal Hugoniot of fluid metals (UHFM) with MMC at sufficiently extreme pressures and temperatures.

296 34 patients (68 eyes) that had LASIK without MMC application.

297 riod, stratified by age, sex, and race.A 1-y MMC in 2015 would increase the average national F&V cons

298 A 1-y MMC would be 35% less effective in preventing CVD deaths

299 25,800 (95% UI 24,300-28,500) DPPs for a 1-y MMC, or the approximately 31,000 (95% UI 26,800-35,300)

300 With a 15-y MMC, increased F&V consumption would be sustained, yield